{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:05:09Z","timestamp":1761156309836,"version":"3.37.3"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.1093\/cid\/cix289","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T11:09:57Z","timestamp":1495537797000},"page":"13-19","source":"Crossref","is-referenced-by-count":21,"title":["Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study"],"prefix":"10.1093","volume":"65","author":[{"given":"Jordan J","family":"Feld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alnoor","family":"Ramji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D","family":"Shafran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Huchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Louise","family":"Vachon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evguenia S","family":"Svarovskaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K C","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chohee","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Massetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana M","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Greenbloom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Borgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G","family":"Swain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"key\n\t\t\t\t20170920205547_CIT0001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170920205547_CIT0002","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170920205547_CIT0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jvh.12350","article-title":"Historical epidemiology of hepatitis C virus (HCV) in select countries\u2014volume 2","volume":"22","year":"2015","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20170920205547_CIT0004","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3748\/wjg.v22.i4.1684","article-title":"Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data","volume":"22","year":"2016","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20170920205547_CIT0005","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2893.2011.01481.x","article-title":"Role of hepatitis C virus genotype 3 in liver fibrosis progression\u2014a systematic review and meta-analysis","volume":"18","year":"2011","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20170920205547_CIT0006","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity","volume":"33","year":"2001","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170920205547_CIT0007","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Swiss Hepatitis C Cohort Study Group","year":"2009","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170920205547_CIT0008","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170920205547_CIT0009","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV","volume":"60","year":"2014","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170920205547_CIT0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170920205547_CIT0011","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/apt.12601","article-title":"Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection","volume":"39","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170920205547_CIT0012","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","year":"2015","journal-title":"Hepatology"},{"volume-title":"Harvoni (ledipasvir and sofosbuvir) tablets: US prescribing information","year":"2016","author":"Gilead Sciences","key":"key\n\t\t\t\t20170920205547_CIT0013"},{"key":"key\n\t\t\t\t20170920205547_CIT0014","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","article-title":"Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170920205547_CIT0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","article-title":"Review article: HCV genotype 3\u2014the new treatment challenge","volume":"39","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170920205547_CIT0016","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"ASTRAL-2 Investigators; ASTRAL-3 Investigators","year":"2015","journal-title":"N Engl J Med"},{"author":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America","key":"key\n\t\t\t\t20170920205547_CIT0017"},{"key":"key\n\t\t\t\t20170920205547_CIT0018","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"European Association for the Study of the Liver","year":"2015","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170920205547_CIT0019","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","article-title":"In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170920205547_CIT0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170920205547_CIT0021","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170920205547_CIT0022","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature14899","article-title":"SEC14L2 enables pan-genotype HCV replication in cell culture","volume":"524","year":"2015","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170920205547_CIT0023","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"AI444040 Study Group","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170920205547_CIT0024","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.01874-12","article-title":"In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170920205547_CIT0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","year":"2013","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20170920205547_CIT0026","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170920205547_CIT0027","first-page":"S484","article-title":"GS-5816 a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier [abstract 1191]. In: 48th annual meeting of the European Association for the Study of the Liver, Amsterdam, 24\u201328 April 2013","volume":"58","year":"2013","journal-title":"J Hepatol"},{"article-title":"Deep sequencing of HCV NS5A from a 3-day study of GS-5816 monotherapy confirms the potency of GS-5816 against pre-existing genotype 1\u20133 NS5A resistance-associated variants [abstract 470]","volume-title":"In: 64th Annual Meeting of the American Association for the Study of Liver Diseases","year":"2013","key":"key\n\t\t\t\t20170920205547_CIT0028"},{"volume-title":"Epclusa (sofosbuvir and velpatasvir) tablets: US prescribing information","year":"2016","key":"key\n\t\t\t\t20170920205547_CIT0029"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/1\/13\/19982341\/cix289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T20:55:59Z","timestamp":1505940959000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/65\/1\/13\/3850783\/LedipasvirSofosbuvir-Plus-Ribavirin-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,23]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix289","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}